Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”

Haolong Li, Song Liu, Xu Wang, Li Wang, Tengda Xu, Yongzhe Li

Clin Mol Hepatol. 2025;31(2):e194-e196. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0181

View: 797 Download: 32

Editorial

Is AMA M2 a useful serologic test for screening high-risk patients for PBC?: Editorial on “Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive”

Nae-Yun Heo

Clin Mol Hepatol. 2025;31(2):640-641. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0117

View: 933 Download: 33 Web of Science: 1 Crossref: 1

Original Article

Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive

Haolong Li, Song Liu, Xu Wang, Xinxin Feng, Siyu Wang, Yanli Zhang, Fengchun Zhang, Li Wang, Tengda Xu, Yongzhe Li

Clin Mol Hepatol. 2025;31(2):474-488. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0416

View: 1662 Download: 154 Web of Science: 3 Crossref: 3

Editorial

Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details: Editorial on “Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis”

Kyung-Ah Kim

Clin Mol Hepatol. 2025;31(1):275-276. Published online October 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0827

View: 1355 Download: 46

Review

Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment

Atsumasa Komori, Yuki Kugiyama

Clin Mol Hepatol. 2025;31(1):90-104. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0821

View: 2088 Download: 225 Web of Science: 1 Crossref: 1

Reply to Correspondence

Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”

Byoung Kuk Jang

Clin Mol Hepatol. 2024;30(2):297-298. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0210

View: 2579 Download: 46

Original Article

JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis

Li Xie, Hui Chen, Li Zhang, Yue Ma, Yuan Zhou, Yong-Yu Yang, Chang Liu, Yu-Li Wang, Ya-Jun Yan, Jia Ding, Xiao Teng, Qiang Yang, Xiu-Ping Liu, Jian Wu

Clin Mol Hepatol. 2024;30(2):206-224. Published online January 8, 2024

DOI: https://doi.org/10.3350/cmh.2023.0506

View: 6111 Download: 264 Web of Science: 5 Crossref: 5

Editorial

JCAD, a new potential therapeutic target in cholestatic liver disease

Byoung Kuk Jang

Clin Mol Hepatol. 2024;30(2):166-167. Published online March 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0128

View: 3228 Download: 81 Web of Science: 1 Crossref: 1

Letter to the Editor

Forms of cholangitis to be considered after SARS-CoV-2 infection

Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim

Clin Mol Hepatol. 2022;28(4):929-930. Published online September 8, 2022

DOI: https://doi.org/10.3350/cmh.2022.0260

View: 3518 Download: 70 Web of Science: 2 Crossref: 3

Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study

Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung

Clin Mol Hepatol. 2022;28(4):926-928. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0233

View: 3477 Download: 80 Web of Science: 2 Crossref: 3

Clinical and serological prognostic markers in primary biliary cholangitis

Markus Wilhelmi

Clin Mol Hepatol. 2021;27(2):360-361. Published online March 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0088

View: 4759 Download: 120

Review

Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea

Sook-Hyang Jeong

Clin Mol Hepatol. 2018;24(1):10-19. Published online January 5, 2018

DOI: https://doi.org/10.3350/cmh.2017.0066

View: 12571 Download: 298 Web of Science: 19 Crossref: 18

1 |

Viewed By 11968	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7499	MAFLD: How is it different from NAFLD?
Viewed By 6574	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5750	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 5377	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 355	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 331	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 223	MAFLD: How is it different from NAFLD?
Cited By 114	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 110	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search